| 5 0.51 (11.36%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.7 | 1-year : | 5.94 |
| Resists | First : | 4.02 | Second : | 5.09 |
| Pivot price | 2.92  |
|||
| Supports | First : | 2.29 | Second : | 1.91 |
| MAs | MA(5) : | 3 |
MA(20) : | 3.18 |
| MA(100) : | 2.7 |
MA(250) : | 2.59 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 52.6 |
D(3) : | 39.9 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 5.09 | Low : | 1.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VACC ] has closed below upper band by 5.1%. Bollinger Bands are 57.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.19 - 3.21 | 3.21 - 3.23 |
| Low: | 2.97 - 3 | 3 - 3.02 |
| Close: | 3.12 - 3.15 | 3.15 - 3.18 |
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Mon, 06 Nov 2023
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy ... - Yahoo Finance
Mon, 30 Oct 2023
What is the Market's View on Vaccitech PLC - ADR (VACC) Stock's Price and Volume Trends Monday? - InvestorsObserver
Tue, 26 Sep 2023
Vaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutions - Yahoo Finance
Mon, 25 Sep 2023
Alliance Global Partners Initiates Coverage on Vaccitech with Buy Rating and 12 Price Target - Best Stocks
Mon, 25 Sep 2023
Morgan Stanley Downgrades Vaccitech - 24/7 Wall St. - 24/7 Wall St.
Mon, 25 Sep 2023
Healthcare Stocks on the Move Monday: RNAZ, VACC, BPTS, CARM, SCYX, MORF, AXLA, APLT - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 2.83e+007 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.291e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 717.9 % |
| Return on Equity (ttm) | -15.2 % |
| Qtrly Rev. Growth | 1.342e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.34 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 9.04 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 159220 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|